Transgene Appoints Seasoned Industry Executive Emmanuelle Quilès to Board of Directors as Independent Director Strasbourg, France, July 9, 2025, 5:45 p.m. CET — Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced the appointment of Emmanuelle Quilès as an independent Director to its Board of Directors. She succeeds Philippe Archinard, who is retiring from the Board. Emmanuelle Quilès brings more than 25 years of experience in strategic leadership roles across the global pharmaceutical industry...
Transgene nomme une experte de l’industrie pharmaceutique, Emmanuelle Quilès, en tant qu’administratrice indépendante au Conseil d’administration Strasbourg, France, 9 juillet 2025, 17 h 45 CET — Transgene (Euronext Paris : TNG), société de biotechnologie qui conçoit et développe des immunothérapies reposant sur des vecteurs viraux contre les cancers, annonce la nomination d’Emmanuelle Quilès en tant qu’administratrice indépendante au sein du Conseil d’administration. Elle succède à Philippe Archinard qui a souhaité quitter le Conseil. Emmanuelle Quilès possède plus de 25 ans d’expérience...
Balance sheet of the liquidity contract with Natixis Oddo BHF SCA as of June 30, 2025 Strasbourg, July 8, 2025 – 06:00 pm CET Under the liquidity contract entrusted by Transgene to Natixis Oddo BHF SCA, as of June 30, 2025, the following resources were managed through the liquidity account: 327 750 shares€ 112,376 In the first half of 2025, it was negotiated a total of: Purchases249,004 shares€ 180,297769 market transactionsSales280,915 shares€ 212,020967 market transactions It is recalled that: as of December 31, 2024, the following resources were managed through the liquidity acc...
Bilan du Contrat de Liquidité avec la Société Natixis Oddo BHF SCA au 30 juin 2025 Strasbourg, le 8 juillet 2025 – 18h00 Au titre du contrat de liquidité confié par Transgene à Natixis Oddo BHF SCA, à la date du 30 juin 2025, les moyens suivants figuraient au compte de liquidité : 327 750 titres Transgene112 376 € Au cours du premier semestre 2025, il a été négocié un total de : Achat249 004 titres180 297 €769 transactionsVente280 915 titres212 020 €967 transactions Il est rappelé : que lors du dernier bilan du 31 décembre 2024, les moyens suivants figuraient au compte de liquidité : ...
Transgene presented two-year follow-up results from their Ph1 trial of TG4050, an individualised neoantigen therapeutic cancer vaccine, at ASCO. The data demonstrated clinical proof of principle in the adjuvant treatment of head and neck cancer.
Transgene presented two-year follow-up results from their Ph1 trial of TG4050, an individualised neoantigen therapeutic cancer vaccine, at ASCO. The data demonstrated clinical proof of principle in the adjuvant treatment of head and neck cancer. TG4050 monotherapy generated durable immune responses lasting up to two years and met all trial endpoints, including disease-free survival, immune activation and safety. Remarkably, 100% of patients treated with TG4050 remained disease-free - an exceptio...
Transgene Completes Initial Patient Screening in Phase II Part of TG4050 Trial in Operable Head and Neck Cancer Phase I part showed 100% Disease-Free Survival (DFS) after a minimum of 2-year follow-up – providing clinical proof of principle for TG4050 Randomization of all patients expected to be completed by end 2025 First immunogenicity data of Phase II part expected in H2 2026 Preliminary efficacy data expected in H2 2027 Strasbourg, France, June 19, 2025, 8:00 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for th...
Transgene finalise la sélection initiale de patients pour la partie Phase II de l’essai avec TG4050 dans le cancer de la tête et du cou opérable 100 % de survie sans récidive après au moins deux ans de suivi des patients de la partie Phase I de l’essai – preuve de principe clinique démontrée pour TG4050 La randomisation des patients devrait être finalisée d’ici la fin de l’année 2025 Les premières données d’immunogénicité de la partie Phase II sont attendues au deuxième semestre 2026 Les données préliminaires d’efficacité sont attendues au deuxième semestre 2027 Strasbourg, France, 1...
Feedback of the companies present at the ODDO BHF Nextcap Forum Company Country Market cap. (m) Company Country Market cap. (m) Accsys Technologies € 124 Hoffmann Green € 62 Afyren € 72 Hornbach € 1 451 Altri € 1 058 IDI € 537 AMG € 550 Implenia CHF 973 AmRest PLN 3 544 Jacquet Metals € 494 Arcure € 29 Kloeckner & Co € 653 Arverne 194 Knaustabbert € 144 Austriacard Holdings € 188 Lna Santé € 270 Bastide € 218 Medincell € 398 Befesa € 1 116 Nacon € 63 CAF € 1 649 N...
Our 14th edition of the ODDO BHF Nextcap Forum took place on 11 June in Paris, and on 12 June virtually. 96 companies and 170 investors were present for more than 700 meetings organized. Overall, we noted a still cautious tone from companies, with limited visibility on a solid rebound in a persistently uncertain market environment (geopolitical situation, US politics, etc.), even if there are some signs of recovery and certain sectors remain very well positioned (leisure, energy, defence). At th...
Medincell’s FY24 results primarily focused on balance sheet items and a recap of corporate achievements. Importantly, Uzedy’s TRx data continues to show sustained momentum, which we view as a key metric to forecast future growth - we maintain our expectation of accelerating sales into FY25 (FYe: US
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.